Associations between an MDM2 gene polymorphism and ulcerative colitis by ARMS-PCR

Article information

Genomics Inform. 2020;18.e9

Publication date (electronic) : 2020 March 31

doi : https://doi.org/10.5808/GI.2020.18.1.e9

Mahsa Sadat Hashemi Doulabi¹, Reza Goleyjani Moghaddam², Ali Salehzadeh^3,

¹Young Researchers and Elite Club, Tonekabon Branch, Islamic Azad University, Tonekabon 46841-61167, Iran

²Department of Biology, Tonekabon Branch, Islamic Azad University, Tonekabon 46841-61167, Iran

³Department of Biology, Rasht Branch, Islamic Azad University, Rasht 41476-54919, Iran

^*Corresponding author: E-mail: salehzadeh@iaurasht.ac.ir

Received 2020 February 11; Revised 2020 February 26; Accepted 2020 February 26.

Abstract

Introduction

Inflammatory bowel disease (IBD) is a complex disease that results from an inappropriate immune system response to intestinal bacteria [1]. IBD is generally subdivided into Crohn disease and ulcerative colitis . Ulcerative colitis is characterized by chronic inflammation of the colon and rectum, whereas Crohn disease can affect the entire digestive system. The role of genetic factors in these conditions was first raised by epidemiological studies that reported familial associations of these diseases [2].

Ulcerative colitis is a chronic inflammatory disease that affects the entire colon [3]. In ulcerative colitis, inflammation is classically confined to the colon, is typically persistent, and begins in the rectum [4]. The presence of abnormal gastrointestinal lesions in patients with ulcerative colitis and intermittent colitis is of major clinical importance, and many gastroenterologists therefore perform upper endoscopy to obtain a definitive diagnosis in patients with IBD [5].

The risk factors for ulcerative colitis appear to be related to changes in the intestinal microbiome or disorders in the intestinal mucosa [6,7]. Intestinal infections, non-steroidal anti-inflammatory drugs, and antibiotics all contribute to the development of IBD [7,8].

MDM2 is a phospho-protein and a ubiquitin ligase for p53 that is responsible for inhibiting p53 activity and promoting its destruction [9]. Recently, a T>G substitution in the MDM2 gene promoter (rs309) has been identified. This substitution is associated with increased expression of MDM2, which accelerates the formation of several types of tumors, resulting in a tendency for them to occur at a younger age [10]. These findings underscore the importance of this polymorphism as an important factor that can affect the frequency of cancer in a population, the age of cancer in individuals, and individuals’ responses to cancer treatment [11].

The rs309 locus in the second promoter region of the MDM2 gene, which is associated with increased expression of this gene, may have potential as a molecular target for cancer susceptibility and as suitable tumor marker. If a polymorphism is present at the rs309 position of the MDM2 gene (i.e., a T>G conversion in this promoter region), the binding affinity of the SP1 transcription factor activator to this region is significantly increased, which increases MDM2 gene expression. This means that an individual with a TT genotype for this polymorphism has a baseline expression level of the MDM2 gene, but in an individual with the TG genotype, the G allele increases MDM2 gene expression, and this expression is even more dramatically increased in individuals with a GG phenotype. Due to the inhibitory effect of MDM2 on p53, an increase in MDM2 expression leads to a decrease in the intracellular amount of p53 protein, which is a key regulator of the response to cellular damage. Under usual circumstances, levels of the p53 protein are increased 5- to 14-fold when cellular damage occurs, but they are reduced by 2 to 3 times if the G allele is present in the rs309 locus of MDM2, which leads to increased levels of the MDM2 protein [12]. The overall aim of this study was to investigate the rs309 polymorphism of MDM2 and its association with ulcerative colitis, and a secondary aim was to explore the association between this polymorphism and the risk of cancer.

Methods

MDM2 rs309 polymorphism

The amplification-refractory mutation system polymerase chain reaction (ARMS-PCR) technique was used to study nucleotide changes in the MDM2 gene. In this technique, the reaction can be performed in a tube. In this study, the ARMS technique was used to determine the presence of the T>G point mutation with two primer pairs (Tables 1 and 2).

Table 1.

The sequences of the primers used in this study

Table 2.

Thermocycler program for MDM2 gene amplification

A proliferation fragment of 224 bp should be seen in all samples as an indicator of the accuracy of PCR. The expected results of ARMS-PCR in this study included the normal genotype (TT), as well as the TG and GG mutant genotypes. After PCR, the products were separated on an agarose gel by electrophoresis and then bands were observed using ultraviolet visualization (Fig. 1).

Fig. 1.

Amplification-refractory mutation system polymerase chain reaction technique of MDM2 codon 309 polymorphism. Line 1, 224 bands of PCR accuracy and 158 bands of homozygous dominant (GG); line 2, 224 bands PCR accuracy and 158 homozygous dominant (GG) bands; line 3, 224 bands PCR 122 and 158 heterozygous TG bands; line 4, 224 bands PCR accuracy and 122 TT homozygous recessive bands; line M, molecular marker 100 bp.

Results

The characteristics of the participants with ulcerative colitis and the control sample are summarized in Table 2. The mean age of the patients with ulcerative colitis was 46.5 years (range, 28 to 69 years) and that of the control individuals was 45.3 years (range, 26 to 71 years).

The presence of ulcerative colitis was significantly related with age (p < 0.05 [chi-square test]). However, it was not significantly related with sex (p > 0.05 [chi-square test]) (Table 3).

Table 3.

Demographic characteristics of patients with ulcerative colitis and controls

Association of the MDM2 polymorphism with the risk of ulcerative colitis

Table 4 shows the allelic frequency of the MDM2 rs309 polymorphism and the distribution of genotypes. The G allele was present in 48.27% of the ulcerative colitis patients and in 56.09% of the control individuals. The distribution of the MDM2 genotype in the ulcerative colitis patients was as follows: TT, 37.93%; TG, 27.59%; and GG, 34.48%. This was significantly different from the distribution in the control individuals (GG genotype: 34.48% vs. 43.90%; p < 0.05).

Table 4.

Genotype and allele frequency of MDM2 in patients with ulcerative colitis and controls

People with the GG phenotype of the MDM2 gene were more prone to ulcerative colitis (odds ratio, 7.142; 95% confidence interval, 2.400 to 9.542) than those with the TT genotype. The heterozygous genotype of this polymorphism did not show a clear relationship with the risk of ulcerative colitis, but we could nonetheless identify the G allele as risky (Table 4).

Discussion

In 2005, Sotamaa et al. [13] conducted a study on the MDM2 gene polymorphism at rs309 in patients with intestinal cancer that included 93 patients and 100 controls. The allelic frequencies of polymorphisms in the patients and control individuals showed Hardy-Weinberg equilibrium, and there was no significant relationship between age and occurrence of this polymorphism [13].

In our study, the polymorphism at this locus was investigated using ARMS-PCR, and a significant relationship was found between the presence of the GG genotype and the incidence of ulcerative colitis disease. A significant relationship was also found between age and ulcerative colitis , but no significant relationship was found for sex.

In 2014 study by Enokida et al. [14] on the rs309 MDM2 gene polymorphism in lung cancer, the distribution of genotypes showed no significant difference between lung cancer patients and controls (patients: TT, 20.1%; TG, 49.7%; and GG, 30.2%; controls: TT, 21.7%; TG, 47.9%; and GG, 30.4%).

In our study, we found that there was a significant relationship between age and genotype, our results were inconsistent with some previous studies. The distribution of the MDM2 genotype in ulcerative colitis patients was as follows: TT, 37.93%; TG, 27.59%; and GG, 34.48%. This distribution was significantly different from that observed in controls (TT, 31.70%; TG, 24.40%; and GG, 43.90%).

Mutations in the P53 gene have been identified in most human cancers, as well as in its downstream signaling pathways, which are mediated by the P21 and MDM2 genes; therefore, proper functioning of all three genes is important for the normal function of cells. Consequently, when mutations in any of these genes disrupt critical signaling pathways, they can result in malignancies in human cells [11].

Many studies have found MDM2 gene mutations in the intestinal system to be associated with cancer [15]. In the current study, the overall aim was to investigate the polymorphism of this gene at rs309 and its association with ulcerative colitis, but a secondary goal was to explore the association between this polymorphism and the risk of cancer.

Since the distribution of the MDM2 polymorphism in individuals with ulcerative colitis was approximately the same as, it can be concluded that ulcerative colitis is a precedes for the development of ulcers into malignancies.

In this study, it was found that the T>G polymorphism at the rs309 locus of the MDM2 gene was associated with ulcerative colitis through a statistical analysis. A direct relationship was found between age and ulcerative colitis, while no relationship was found for sex.

Since this gene is directly associated with carcinogenesis (mutation and loss of function), it can be concluded that the occurrence of intestinal inflammation and subsequent ulceration lays the groundwork for subsequent cancer.

Article information Continued